← Back to Clinical Trials
Recruiting NCT07513740

NCT07513740 PENG vs Deep Iliacus Plane Block in Intertrochanteric Femur Fractures

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07513740
Status Recruiting
Phase
Sponsor Erzincan Binali Yildirim Universitesi
Condition Postoperative Analgesia
Study Type INTERVENTIONAL
Enrollment 75 participants
Start Date 2026-03-01
Primary Completion 2027-03-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 75 Years
Study Type INTERVENTIONAL
Interventions
Intravenous AnalgesiaPericapsular nerve group (PENG) blockDeep Iliacus Plane Block (DIPB)

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 75 participants in total. It began in 2026-03-01 with a primary completion date of 2027-03-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Intertrochanteric femur fractures are common in elderly patients and are associated with significant pain. Providing effective analgesia is clinically important both during positioning for spinal anesthesia and in the postoperative period in this patient population. The Pericapsular Nerve Group (PENG) block is a regional anesthesia technique that targets the articular branches of the hip capsule and may provide effective analgesia with motor-sparing potential. The Deep Iliacus Plane Block (DIPB) is a newer approach that may spread to both the articular branches and the lateral femoral cutaneous nerve. Although both blocks are used in patients with intertrochanteric fractures, there is a lack of sufficient randomized controlled data comparing their effectiveness for pain during positioning for spinal anesthesia and for postoperative analgesia. Therefore, it is important to determine which technique provides greater clinical benefit. The aim of this study is to compare the analgesic efficacy of the PENG block and the Deep Iliacus Plane Block during positioning for spinal anesthesia and in the postoperative period in patients undergoing surgery for intertrochanteric femur fractures.

Eligibility Criteria

Inclusion Criteria: * Patients scheduled for elective surgery for intertrochanteric femur fractures * Patients with ASA physical status I, II, or III * Patients aged between 30 and 85 years Exclusion Criteria: * Patients with ASA physical status IV or higher * Patients undergoing emergency surgery * Patients who refuse to participate or withdraw consent during the study * Patients with cognitive dysfunction such as Alzheimer's disease, dementia, or delirium * Patients with a history of local anesthetic toxicity * Patients with infection at the planned block site * Patients with bleeding diathesis * Patients undergoing additional surgical procedures or additional anesthesia (e.g., general anesthesia) * Patients with a history of chronic opioid use or receiving treatment for neuropathic pain

Contact & Investigator

Central Contact

Taha Emre ÖTÜGEN

✉ tahaemreotugen@gmail.com

📞 +905307060125

Frequently Asked Questions

Who can join the NCT07513740 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Postoperative Analgesia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07513740 currently recruiting?

Yes, NCT07513740 is actively recruiting participants. Contact the research team at tahaemreotugen@gmail.com for enrollment information.

Where is the NCT07513740 trial being conducted?

This trial is being conducted at Erzincan, Turkey (Türkiye).

Who is sponsoring the NCT07513740 clinical trial?

NCT07513740 is sponsored by Erzincan Binali Yildirim Universitesi. The trial plans to enroll 75 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology